复星医药：前三季度净利润同比增长26% 创新药品收入稳健增长

Core Viewpoint - Fosun Pharma reported a decline in revenue for Q3 2025, primarily due to the impact of centralized drug procurement, while net profit showed a positive growth trend [1] Financial Performance - Q3 2025 revenue reached 9.879 billion yuan, a year-on-year decrease of 5.46% [1] - Net profit attributable to shareholders for Q3 2025 was 821 million yuan, an increase of 4.52% year-on-year [1] - For the first three quarters of 2025, total revenue was 29.393 billion yuan, down 4.91% year-on-year [1] - Net profit attributable to shareholders for the first three quarters was 2.523 billion yuan, reflecting a year-on-year growth of 25.50% [1] Market Impact - The decline in revenue for the first three quarters and Q3 was mainly influenced by the continuation of centralized drug procurement and the initiation of such programs in certain regions [1] - Despite the revenue decline, the income from innovative drugs showed steady growth during the same period [1]